


CONFIDENTIAL



NOTICE OF DIETARY SUPPLEMENT DESCRIPTIVE CLAIM 5 2002
21 CFR 101.93

To: Office of Nutritional Products, Labeling And Dietary Supplements (HFS-810) Center for Food Safety and Applied Nutrition Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740	From: StarCor Pharmaceuticals, Inc. 2500 SW 17 th Road, Building 100, Suite 101 Ocala, Florida 34474 Telephone: 352-861-9301 Fax: 352-237-6119
--	---

Authority:	21 CFR 101.93 (Notification of statement listed in Section 403 (r)(6) of the Federal Food, Drug, and Cosmetic Act.)
Name Bearing Statement:	Manufacturer/Labeler/Distributor StarCor Pharmaceuticals, Inc.
Address:	2500 SW 17 th Road, Building 100, Suite 101, Ocala, FL 34474
Statement(s) Text:	Male sexual health; Male hormone precursor; A natural complement for maintaining health; Extended release formulation to support consistent physiologic testosterone biosynthesis and blood levels; Promotes normal male sexual function and sense of well being; Helps maintain muscle mass and bone density; Dietary supplement.
Dietary Ingredient(s):	Androstenedione extended release; Serving size: 1 tablet/amount per tablet: Androstenedione (50mg)
Other Ingredient(s):	Calcium phosphate; Cellulose; Vegetable stearates; Silicon dioxide; Polyethylene glycol
Brand/Trade Name:	Androl XL™
Disclaimer:	Pursuant to 21 CFR 101.93(b),(c),(d),(e), the following disclaimer appears on all product labels and other printed materials: "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

Dietary Supplement Claim Notice/StarCor Pharmaceuticals
Androl XL™
February, 2002

97S 0162 LET 9610

NOTICE OF DIETARY SUPPLEMENT DESCRIPTIVE CLAIM

- Page Two -

Responsible Individual: D. Russell Locke, M.D.

Title: President

Address: 2500 SW 17th Road, Building 100, Suite 101, Ocala, FL 34474

Certification: I, D. Russell Locke, M.D., hereby certify that the information contained in this notice is complete and accurate and that StarCor Pharmaceuticals has substantiated that the product statements herein are truthful and not misleading. Said certification is hereby made pursuant to 21 CFR 101.93.

Signature:


D. Russell Locke, M.D.

Date:

2/27/02


Attorney Representative:

Paula A. Willis
Attorney for StarCor Pharmaceuticals, Inc.
2500 SW 17th Road, Building 100, Suite 101
Telephone: 352-861-9301
Fax: 352-237-6119

Certificate of Service:

I hereby certify that the original and two copies of this Notice of Dietary Supplement Descriptive Claim is furnished on the 28 day of February, 2002, by U.S. Certified Mail/Return Receipt to the Office of Nutritional Products, Labeling and Dietary Supplements (HFS-810), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5100 Paint Branch Parkway, College Park MD 20740.

Attorney Signature:


Paula A. Willis, Esquire

Date:

2/28/02